Cargando…
Comprehensive Mechanistic View of the Hydrolysis of Oxadiazole-Based Inhibitors by Histone Deacetylase 6 (HDAC6)
[Image: see text] Histone deacetylase (HDAC) inhibitors used in the clinic typically contain a hydroxamate zinc-binding group (ZBG). However, more recent work has shown that the use of alternative ZBGs, and, in particular, the heterocyclic oxadiazoles, can confer higher isoenzyme selectivity and mor...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Chemical Society
2023
|
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10367051/ https://www.ncbi.nlm.nih.gov/pubmed/37392419 http://dx.doi.org/10.1021/acschembio.3c00212 |
_version_ | 1785077304862441472 |
---|---|
author | Motlová, Lucia Šnajdr, Ivan Kutil, Zsófia Andris, Erik Ptáček, Jakub Novotná, Adéla Nováková, Zora Havlínová, Barbora Tueckmantel, Werner Dráberová, Helena Majer, Pavel Schutkowski, Mike Kozikowski, Alan Rulíšek, Lubomír Bařinka, Cyril |
author_facet | Motlová, Lucia Šnajdr, Ivan Kutil, Zsófia Andris, Erik Ptáček, Jakub Novotná, Adéla Nováková, Zora Havlínová, Barbora Tueckmantel, Werner Dráberová, Helena Majer, Pavel Schutkowski, Mike Kozikowski, Alan Rulíšek, Lubomír Bařinka, Cyril |
author_sort | Motlová, Lucia |
collection | PubMed |
description | [Image: see text] Histone deacetylase (HDAC) inhibitors used in the clinic typically contain a hydroxamate zinc-binding group (ZBG). However, more recent work has shown that the use of alternative ZBGs, and, in particular, the heterocyclic oxadiazoles, can confer higher isoenzyme selectivity and more favorable ADMET profiles. Herein, we report on the synthesis and biochemical, crystallographic, and computational characterization of a series of oxadiazole-based inhibitors selectively targeting the HDAC6 isoform. Surprisingly, but in line with a very recent finding reported in the literature, a crystal structure of the HDAC6/inhibitor complex revealed that hydrolysis of the oxadiazole ring transforms the parent oxadiazole into an acylhydrazide through a sequence of two hydrolytic steps. An identical cleavage pattern was also observed both in vitro using the purified HDAC6 enzyme as well as in cellular systems. By employing advanced quantum and molecular mechanics (QM/MM) and QM calculations, we elucidated the mechanistic details of the two hydrolytic steps to obtain a comprehensive mechanistic view of the double hydrolysis of the oxadiazole ring. This was achieved by fully characterizing the reaction coordinate, including identification of the structures of all intermediates and transition states, together with calculations of their respective activation (free) energies. In addition, we ruled out several (intuitively) competing pathways. The computed data (ΔG(‡) ≈ 21 kcal·mol(–1) for the rate-determining step of the overall dual hydrolysis) are in very good agreement with the experimentally determined rate constants, which a posteriori supports the proposed reaction mechanism. We also clearly (and quantitatively) explain the role of the −CF(3) or −CHF(2) substituent on the oxadiazole ring, which is a prerequisite for hydrolysis to occur. Overall, our data provide compelling evidence that the oxadiazole warheads can be efficiently transformed within the active sites of target metallohydrolases to afford reaction products possessing distinct selectivity and inhibition profiles. |
format | Online Article Text |
id | pubmed-10367051 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | American Chemical Society |
record_format | MEDLINE/PubMed |
spelling | pubmed-103670512023-07-26 Comprehensive Mechanistic View of the Hydrolysis of Oxadiazole-Based Inhibitors by Histone Deacetylase 6 (HDAC6) Motlová, Lucia Šnajdr, Ivan Kutil, Zsófia Andris, Erik Ptáček, Jakub Novotná, Adéla Nováková, Zora Havlínová, Barbora Tueckmantel, Werner Dráberová, Helena Majer, Pavel Schutkowski, Mike Kozikowski, Alan Rulíšek, Lubomír Bařinka, Cyril ACS Chem Biol [Image: see text] Histone deacetylase (HDAC) inhibitors used in the clinic typically contain a hydroxamate zinc-binding group (ZBG). However, more recent work has shown that the use of alternative ZBGs, and, in particular, the heterocyclic oxadiazoles, can confer higher isoenzyme selectivity and more favorable ADMET profiles. Herein, we report on the synthesis and biochemical, crystallographic, and computational characterization of a series of oxadiazole-based inhibitors selectively targeting the HDAC6 isoform. Surprisingly, but in line with a very recent finding reported in the literature, a crystal structure of the HDAC6/inhibitor complex revealed that hydrolysis of the oxadiazole ring transforms the parent oxadiazole into an acylhydrazide through a sequence of two hydrolytic steps. An identical cleavage pattern was also observed both in vitro using the purified HDAC6 enzyme as well as in cellular systems. By employing advanced quantum and molecular mechanics (QM/MM) and QM calculations, we elucidated the mechanistic details of the two hydrolytic steps to obtain a comprehensive mechanistic view of the double hydrolysis of the oxadiazole ring. This was achieved by fully characterizing the reaction coordinate, including identification of the structures of all intermediates and transition states, together with calculations of their respective activation (free) energies. In addition, we ruled out several (intuitively) competing pathways. The computed data (ΔG(‡) ≈ 21 kcal·mol(–1) for the rate-determining step of the overall dual hydrolysis) are in very good agreement with the experimentally determined rate constants, which a posteriori supports the proposed reaction mechanism. We also clearly (and quantitatively) explain the role of the −CF(3) or −CHF(2) substituent on the oxadiazole ring, which is a prerequisite for hydrolysis to occur. Overall, our data provide compelling evidence that the oxadiazole warheads can be efficiently transformed within the active sites of target metallohydrolases to afford reaction products possessing distinct selectivity and inhibition profiles. American Chemical Society 2023-07-03 /pmc/articles/PMC10367051/ /pubmed/37392419 http://dx.doi.org/10.1021/acschembio.3c00212 Text en © 2023 The Authors. Published by American Chemical Society https://creativecommons.org/licenses/by/4.0/Permits the broadest form of re-use including for commercial purposes, provided that author attribution and integrity are maintained (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Motlová, Lucia Šnajdr, Ivan Kutil, Zsófia Andris, Erik Ptáček, Jakub Novotná, Adéla Nováková, Zora Havlínová, Barbora Tueckmantel, Werner Dráberová, Helena Majer, Pavel Schutkowski, Mike Kozikowski, Alan Rulíšek, Lubomír Bařinka, Cyril Comprehensive Mechanistic View of the Hydrolysis of Oxadiazole-Based Inhibitors by Histone Deacetylase 6 (HDAC6) |
title | Comprehensive
Mechanistic View of the Hydrolysis of
Oxadiazole-Based Inhibitors by Histone Deacetylase 6 (HDAC6) |
title_full | Comprehensive
Mechanistic View of the Hydrolysis of
Oxadiazole-Based Inhibitors by Histone Deacetylase 6 (HDAC6) |
title_fullStr | Comprehensive
Mechanistic View of the Hydrolysis of
Oxadiazole-Based Inhibitors by Histone Deacetylase 6 (HDAC6) |
title_full_unstemmed | Comprehensive
Mechanistic View of the Hydrolysis of
Oxadiazole-Based Inhibitors by Histone Deacetylase 6 (HDAC6) |
title_short | Comprehensive
Mechanistic View of the Hydrolysis of
Oxadiazole-Based Inhibitors by Histone Deacetylase 6 (HDAC6) |
title_sort | comprehensive
mechanistic view of the hydrolysis of
oxadiazole-based inhibitors by histone deacetylase 6 (hdac6) |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10367051/ https://www.ncbi.nlm.nih.gov/pubmed/37392419 http://dx.doi.org/10.1021/acschembio.3c00212 |
work_keys_str_mv | AT motlovalucia comprehensivemechanisticviewofthehydrolysisofoxadiazolebasedinhibitorsbyhistonedeacetylase6hdac6 AT snajdrivan comprehensivemechanisticviewofthehydrolysisofoxadiazolebasedinhibitorsbyhistonedeacetylase6hdac6 AT kutilzsofia comprehensivemechanisticviewofthehydrolysisofoxadiazolebasedinhibitorsbyhistonedeacetylase6hdac6 AT andriserik comprehensivemechanisticviewofthehydrolysisofoxadiazolebasedinhibitorsbyhistonedeacetylase6hdac6 AT ptacekjakub comprehensivemechanisticviewofthehydrolysisofoxadiazolebasedinhibitorsbyhistonedeacetylase6hdac6 AT novotnaadela comprehensivemechanisticviewofthehydrolysisofoxadiazolebasedinhibitorsbyhistonedeacetylase6hdac6 AT novakovazora comprehensivemechanisticviewofthehydrolysisofoxadiazolebasedinhibitorsbyhistonedeacetylase6hdac6 AT havlinovabarbora comprehensivemechanisticviewofthehydrolysisofoxadiazolebasedinhibitorsbyhistonedeacetylase6hdac6 AT tueckmantelwerner comprehensivemechanisticviewofthehydrolysisofoxadiazolebasedinhibitorsbyhistonedeacetylase6hdac6 AT draberovahelena comprehensivemechanisticviewofthehydrolysisofoxadiazolebasedinhibitorsbyhistonedeacetylase6hdac6 AT majerpavel comprehensivemechanisticviewofthehydrolysisofoxadiazolebasedinhibitorsbyhistonedeacetylase6hdac6 AT schutkowskimike comprehensivemechanisticviewofthehydrolysisofoxadiazolebasedinhibitorsbyhistonedeacetylase6hdac6 AT kozikowskialan comprehensivemechanisticviewofthehydrolysisofoxadiazolebasedinhibitorsbyhistonedeacetylase6hdac6 AT ruliseklubomir comprehensivemechanisticviewofthehydrolysisofoxadiazolebasedinhibitorsbyhistonedeacetylase6hdac6 AT barinkacyril comprehensivemechanisticviewofthehydrolysisofoxadiazolebasedinhibitorsbyhistonedeacetylase6hdac6 |